Aspirin for Primary Prevention

• Autores: Ilana B. Richman, Douglas K. Owens
• Localización: Medical clinics of North America, ISSN 0025-7125, Vol. 101, Nº. 4, 2017 (Ejemplar dedicado a: Disease Prevention), págs. 713-724
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable uncertainty about whether younger and older patients may benefit.